Multiple Myeloma (MM)Phase 2CAREMM-012NCT07585760
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
A Phase 2 study testing CM336 Plus Isatuximab in people with Multiple Myeloma (MM) and Multiple Myeloma Light Chain Induced Renal Insufficiency, run by Institute of Hematology & Blood Diseases Hospital, China at 1 site in China.
Trial summary
This study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM) accompanied by renal impairment ([eGFR] < 40 mL/min). Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
- What is being tested?
- CM336 Plus Isatuximab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 1 siteChina
- Study dates
- 10 Sep 2026to 30 Dec 2028
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 to 80 years.
- Newly diagnosed symptomatic multiple myeloma (NDMM) according to the International Myeloma Working Group (IMWG) criteria. Patients who have received up to 1 cycle of prior anti-myeloma therapy are allowed to enroll.
- Presence of measurable disease at diagnosis, meeting at least one of the following criteria:
- A.Serum M-protein ≥ 1 g/dL (> 10 g/L) measured by serum protein electrophoresis (SPEP) (for IgA or IgD myeloma, quantitative IgA or IgD levels may be used instead); OR
- B.Urine M-protein ≥ 200 mg/24 hours; OR
- C.If both serum and urine M-protein do not meet the above criteria, an abnormal serum free light chain (FLC) ratio (normal FLC ratio: 0.26 to 1.65) with an involved serum FLC level ≥ 100 mg/L.
Show all 19Show fewer
- Accompanied by myeloma-related renal impairment (RI), defined as an estimated glomerular filtration rate (eGFR) < 40 mL/min (calculated using the Modification of Diet in Renal Disease [MDRD] formula). The type of renal impairment must be restricted to cast nephropathy, which can be confirmed by renal biopsy or by the investigator's clinical judgment based on light chain proteinuria. If urine albumin accounts for more than 30% of the total urine protein, a renal biopsy is mandatory to confirm cast nephropathy.
- Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2.
- Adequate major organ function, meeting the following criteria:
- Hematological function:
- Absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L, and without receiving granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 7 days, or pegylated G-CSF within 14 days prior to testing;
- Hemoglobin ≥ 60 g/L, and without receiving whole blood or red blood cell transfusions within 7 days prior to testing;
- Platelet count ≥ 50 × 10^9/L, and without receiving whole blood, platelet transfusions, or thrombopoietin receptor agonists (TPO-RAs) within 7 days prior to testing.
- Hepatic function:
- Alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN), aspartate aminotransferase (AST) ≤ 3 × ULN, and total bilirubin ≤ 2 × ULN (subjects with a history of Gilbert's syndrome are eligible if direct bilirubin ≤ 2.0 × ULN).
- Coagulation function:
- International Normalized Ratio (INR) or Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.
- No active concomitant malignancies or malignancies with an expected survival of less than 12 months.
- Willingness to participate in the study, good compliance, and ability to sign the informed consent form (ICF).
Who cannot join
- Diagnosis of smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), Waldenström's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, amyloidosis, or secondary plasma cell leukemia.
- Central nervous system (CNS) involvement or clinical evidence of meningeal involvement.
- Severe and/or uncontrolled cardiac diseases, including: unstable angina, symptomatic congestive heart failure, myocardial infarction within 6 months prior to enrollment, severe and uncontrolled arrhythmias; or other cardiovascular/cerebrovascular diseases deemed unsuitable for study participation by the investigator.
- Presence of active infections, including: HIV positive; active Hepatitis B (HBV-DNA positive); active Hepatitis C (HCV-RNA positive); active or latent syphilis infection (Treponema pallidum antibody positive); active tuberculosis (active TB infection indicated by chest imaging or other relevant tests within the past 3 months or during the screening period); or other active infections deemed unsuitable for study participation by the investigator.
- Patients with concurrent malignancies; or severe concomitant diseases that, in the investigator's judgment, would severely compromise patient safety or interfere with study completion.
- Pregnant or lactating women.
Show all 9Show fewer
- History of severe allergic reactions (Grade ≥ 3) or hypersensitivity to any components of the study drugs.
- Unable or unwilling to sign the informed consent form.
- Any other conditions that, in the opinion of the investigator, make the patient unsuitable for enrollment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, 300000
Gang An, PhD & MD, 0086 13502181109, angang@ihcams.ac.cn
About this study
Official title: A Prospective, Single-arm, Single-center, Phase II Study of BCMA/CD3 Bispecific Antibody Combined With CD38 Monoclonal Antibody in Newly Diagnosed Multiple Myeloma Patients With Renal Impairment
This study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM) accompanied by renal impairment ([eGFR] < 40 mL/min). Enrolled subjects will receive three consecutive cycles of induction therapy with CM336 in combination with isatuximab.
- Being tested
- CM336 Plus Isatuximab
- Keywords
- BCMA/CD3 bispecific antibody, CM336
- Medical subject headings
- Multiple Myeloma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CM336 Plus IsatuximabDrug
CM336: Administered subcutaneously (SC) via a step-up dosing regimen, which includes a step-up dosing phase and a target dosing phase. Upon reaching the target dose, it will be administered once weekly.
Isatuximab: Administered intravenously (IV) at a dose of 10 mg/kg, given weekly during Cycle 1, and every two weeks during Cycles 2 and 3.
| Study group | Role | What they receive |
|---|---|---|
| CM336 plus Isatuximab | Experimental | Enrolled patients will receive 3 cycles of induction therapy with CM336 in combination with isatuximab. Receives: Drug: CM336 Plus Isatuximab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Renal Response Rate (Minor Response or better)
The Overall Renal Response Rate is defined as the percentage of participants who achieve a renal response of Minor Response or better (including Minor Response, Partial Response, and Complete Response) according to the International Myeloma Working Group (IMWG) criteria for renal impairment.
Measured: At the end of Cycle 3 (each cycle is 28 days)
Secondary outcomes (7)
Rate of Renal Partial Response or Better
Rate of renal partial response or better is defined as the percentage of participants who achieve a renal response of Partial Response or better (including Partial Response and Complete Response) according to the International Myeloma Working Group (IMWG) criteria for renal impairment.
Measured: At the end of Cycle 3 (each cycle is 28 days)
Hematological Overall Response Rate (ORR)
The percentage of participants who achieve a hematological response of Partial Response (PR) or better (including PR, Very Good Partial Response [VGPR], Complete Response [CR], and Stringent Complete Response [sCR]) according to the International Myeloma Working Group (IMWG) uniform response criteria.
Measured: From the first dose of CM336 through 30 days after the last dose of CM336
MRD Negativity Rate
The percentage of participants who achieve MRD negativity in the bone marrow. MRD negativity is defined by a threshold of 10^-5, assessed via Next-Generation Flow (NGF) cytometry in accordance with IMWG criteria.
Measured: At the end of Cycle 3 (each cycle is 28 days)
Kinetics of Serum Free Light Chain (sFLC) Reduction
The rate and time to achieve a specific percentage or absolute reduction in involved serum free light chain (sFLC) levels from baseline.
Measured: From the first dose of CM336 through 30 days after the last dose of CM336
Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Safety will be assessed by monitoring the incidence, nature, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events of special interest (AESIs) such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), graded according to NCI CTCAE v5.0 and ASTCT criteria. Dose interruptions, modifications, or discontinuations due to toxicity will also be recorded.
Measured: From the first dose of CM336 through 30 days after the last dose of CM336.
PFS
The time from the start of the study treatment to the date of first documented disease progression (according to IMWG criteria) or death from any cause, whichever occurs first.
Measured: From the first dose of CM336 up to the date of first documented disease progression or death, up to approximately 24 months.
OS
The time from the start of the study treatment to the date of death from any cause.
Measured: From the first dose of CM336 up to the date of death from any cause, up to approximately 24 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start10 Sep 2026 (estimated)
- Primary completion1 May 2028 (estimated)
- Study completion30 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple Myeloma (MM)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 26 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07585760
- Sponsor's protocol ID
- IIT2026037
- Acronym
- CAREMM-012
- Status last verified
- Aug 2026
- First submitted
- 13 Apr 2026
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided